ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Genmab AS

Genmab AS (GMAB)

20.31
0.22
(1.10%)
Closed December 21 3:00PM
20.31
0.01
(0.05%)
After Hours: 5:56PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
20.31
Bid
20.06
Ask
20.60
Volume
1,829,681
20.13 Day's Range 20.43
0.00 52 Week Range 0.00
Market Cap
Previous Close
20.09
Open
20.22
Last Trade
10
@
20.31
Last Trade Time
Financial Volume
US$ 37,133,782
VWAP
20.2952
Average Volume (3m)
-
Shares Outstanding
660,745,350
Dividend Yield
-
PE Ratio
31.81
Earnings Per Share (EPS)
6.59
Revenue
16.47B
Net Profit
4.35B

About Genmab AS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biogenetic (human)
Website
Headquarters
Copenhagen, Dnk
Founded
2000
Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GMAB. The last closing price for Genmab AS was US$20.09. Over the last year, Genmab AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genmab AS currently has 660,745,350 shares outstanding. The market capitalization of Genmab AS is US$13.27 billion. Genmab AS has a price to earnings ratio (PE ratio) of 31.81.

GMAB Latest News

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with...

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

  Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New...

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

GMAB - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?
The current share price of Genmab AS is US$ 20.31
How many Genmab AS shares are in issue?
Genmab AS has 660,745,350 shares in issue
What is the market cap of Genmab AS?
The market capitalisation of Genmab AS is USD 13.27B
What is the 1 year trading range for Genmab AS share price?
Genmab AS has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Genmab AS?
The price to earnings ratio of Genmab AS is 31.81
What is the cash to sales ratio of Genmab AS?
The cash to sales ratio of Genmab AS is 8.4
What is the reporting currency for Genmab AS?
Genmab AS reports financial results in DKK
What is the latest annual turnover for Genmab AS?
The latest annual turnover of Genmab AS is DKK 16.47B
What is the latest annual profit for Genmab AS?
The latest annual profit of Genmab AS is DKK 4.35B
What is the registered address of Genmab AS?
The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260
What is the Genmab AS website address?
The website address for Genmab AS is www.genmab.com
Which industry sector does Genmab AS operate in?
Genmab AS operates in the BIOGENETIC (HUMAN) sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
277.63M

GMAB Discussion

View Posts
XenaLives XenaLives 5 years ago

Products in development
Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.


http://www.genmab.com/product-pipeline/products-in-development
👍️0
XenaLives XenaLives 5 years ago

Product pipeline
Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.


http://www.genmab.com/product-pipeline

👍️0
XenaLives XenaLives 5 years ago

About Genmab A/S
Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.


ADDRESS
Kalvebod Brygge 43 Copenhagen V, 1560 Denmark
PHONE
45-7020-2728
WEBSITE
www.genmab.com






https://www.bloomberg.com/quote/GMXAY:US
👍️0
XenaLives XenaLives 5 years ago
GMXAY largest holding in Blackrock fund:

iShares Genomics Immunology and Healthcare ETF


https://www.blackrock.com/us/individual/products/308878/
👍️0
PennyStock Alert PennyStock Alert 5 years ago
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
👍️0
TenKay TenKay 7 years ago
GMXAY Forward Split 5 for 1 effective May 1, 2018

http://otce.finra.org/DailyList
👍️0
trendmkr trendmkr 9 years ago
Here are Two Biotech Stocks to Watch in January - article mentions Genmab

http://marketexclusive.com/here-are-two-biotech-stocks-to-watch-in-january/1228/
👍️0
stocktrademan stocktrademan 10 years ago
$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY

bullish

$GMXAY recent news/filings

## source: finance.yahoo.com

Thu, 04 Dec 2014 06:36:32 GMT ~ Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-063632870.html
*********************************************************

Mon, 24 Nov 2014 13:53:34 GMT ~ Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-ii-study-135334071.html
*********************************************************

Mon, 10 Nov 2014 08:17:15 GMT ~ Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

[GlobeNewswire] - Company Announcement

read full: http://finance.yahoo.com/news/genmab-announces-phase-iii-combination-081715458.html
*********************************************************

Thu, 06 Nov 2014 14:40:06 GMT ~ Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

[GlobeNewswire] - Media Release

read full: http://finance.yahoo.com/news/genmab-announces-daratumumab-ofatumumab-data-144006800.html
*********************************************************

Thu, 06 Nov 2014 14:10:48 GMT ~ Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

[GlobeNewswire] - COPENHAGEN, Denmark -- Genmab A/S (OMX: GEN) announced today additional data from the interim analysis of the ofatumumab (Arzerra(tm)) Phase III study, PROLONG (OMB112517). The study evaluated ofatumumab ...

read full: http://finance.yahoo.com/news/genmab-announces-additional-data-phase-141048186.html
*********************************************************


$GMXAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$GMXAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GMXAY/company-info
Ticker: $GMXAY
OTC Market Place: OTC Pink Current
CIK code: 0001434265
Company name: Genmab A/S
Company website: http://www.genmab.com
Incorporated In: Denmark

Business Description: Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


$GMXAY share structure

## source: otcmarkets.com

Market Value: $2,578,167,309 a/o Dec 03, 2014
Shares Outstanding: 51,052,818 a/o Jul 30, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GMXAY extra dd links

Company name: Genmab A/S
Company website: http://www.genmab.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GMXAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GMXAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GMXAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/news - http://finance.yahoo.com/q/h?s=GMXAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GMXAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GMXAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GMXAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Genmab+A%2FS&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Genmab+A%2FS
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Genmab+A%2FS&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.genmab.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.genmab.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.genmab.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GMXAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434265&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GMXAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GMXAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GMXAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GMXAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GMXAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GMXAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GMXAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GMXAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GMXAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GMXAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GMXAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GMXAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GMXAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GMXAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GMXAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GMXAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GMXAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GMXAY



$GMXAY DD Notes ~ http://www.ddnotesmaker.com/GMXAY
👍️0
akademikeren akademikeren 11 years ago
Genmab has taken a beating along with a lot of american Biotech. It is poised for a lot of news starting the 19th of april with a PDUFA date on their submission on 1st line CLL drug Arzerra. For those of you unfamiliar with this Company I will be posting news regularly and tell you something about the history.
👍️0

Your Recent History

Delayed Upgrade Clock